Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Clene Inc.

Consumer Defensive US CLNN

5.83USD
-0.06(1.02%)

Last update at 2026-06-23T15:00:00Z

Day Range

5.826.11
LowHigh

52 Week Range

2.2813.50
LowHigh

Fundamentals

  • Previous Close 5.89
  • Market Cap74.44M
  • Volume10710
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-21.58800M
  • Revenue TTM0.20M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.16M
  • Diluted EPS TTM-2.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.17300M -39.40000M -49.50400M -29.91800M -10.16800M
Minority interest - - - - -
Net income -26.17300M -39.40000M -49.50400M -15.27900M -9.74000M
Selling general administrative 9.23M 13.31M 14.42M 16.94M 18.81M
Selling and marketing expenses - 1.03M 1.05M - -
Gross profit 0.16M 0.27M 0.53M 0.45M 0.43M
Reconciled depreciation 1.50M 1.65M 1.59M 1.02M 0.95M
Ebit -23.08300M -35.33600M -44.94600M -45.33000M -45.27600M
Ebitda -21.58800M -33.69100M -43.24100M -45.07300M -47.51600M
Depreciation and amortization 1.50M 1.65M 1.71M 0.26M -2.24000M
Non operating income net other - - - 21.79M 40.68M
Operating income -23.08300M -33.09300M -40.54000M -45.33000M -45.27600M
Other operating expenses 23.28M 33.44M 41.19M 45.80M 46.00M
Interest expense 2.68M 4.06M 4.56M 3.30M 0.87M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M -0.42800M
Interest income 0.22M 0.86M 1.39M - -
Net interest income -3.47200M -3.96000M -4.55600M -4.06900M -4.05300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - 1.54M -14.63900M -0.42800M
Total revenue 0.20M 0.34M 0.65M 0.47M 0.72M
Total operating expenses 23.24M 33.37M 41.07M 45.78M 45.71M
Cost of revenue 0.04M 0.07M 0.12M 0.03M 0.29M
Total other income expense net -3.09000M -6.30700M -8.96400M 15.41M 35.11M
Discontinued operations - - - - -
Net income from continuing ops -26.17300M -39.40000M -40.38500M -29.91800M -9.74000M
Net income applicable to common shares - - - -29.91800M -9.74000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 18.13M 27.34M 52.34M 44.49M 63.06M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.75M 3.54M 2.48M 5.65M 0.17M
Total liab 35.72M 36.19M 38.95M 41.26M 50.47M
Total stockholder equity -17.59200M -8.85700M 13.39M 3.24M 12.60M
Deferred long term liab - - - - 18.10M
Other current liab 5.00M 5.10M 3.72M 3.86M 3.61M
Common stock 0.00100M 0.00100M 0.01M 0.00700M 0.00600M
Capital stock 0.00100M 0.00100M 0.01M 0.00700M 0.00600M
Retained earnings -308.29600M -282.12300M -242.72300M -193.21900M -163.30100M
Other liab - - - 2.56M 20.89M
Good will - - - - -
Other assets - - - 0.06M 0.06M
Cash 5.19M 12.15M 28.82M 18.33M 50.29M
Cash and equivalents - - - - -
Total current liabilities 10.78M 10.29M 25.33M 13.86M 6.03M
Current deferred revenue - 2.67M 0.00000M - -
Net debt 16.48M 8.69M 3.34M 13.49M -26.24600M
Short term debt 4.88M 1.28M 20.11M 6.98M 0.49M
Short long term debt 4.07M 0.36M 19.50M 6.42M -
Short long term debt total 21.67M 20.84M 32.16M 31.82M 24.04M
Other stockholder equity 290.53M 273.19M 255.90M 196.25M 175.66M
Property plant equipment - - - 15.24M 5.17M
Total current assets 8.98M 16.16M 38.85M 29.20M 54.58M
Long term investments - - - - -
Net tangible assets - - - 3.24M 12.60M
Short term investments - 0.00000M 6.18M 4.98M -
Net receivables 0.00000M 0.39M 1.34M 0.19M 1.61M
Long term debt 13.54M 15.43M 7.15M 19.25M 14.48M
Inventory 0.04M 0.07M 0.04M 0.04M 0.04M
Accounts payable 0.89M 1.24M 1.50M 3.01M 1.92M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.17M 0.07M 0.20M 0.20M 0.23M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00700M 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -193.21900M -163.30100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.06M 0.06M 0.06M 0.06M
Deferred long term asset charges - - - - -
Non current assets total 9.15M 11.18M 13.49M 15.30M 8.48M
Capital lease obligations 4.06M 5.06M 5.51M 6.15M 4.96M
Long term debt total - - - - 14.48M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00000M 6.32M 7.00M -4.98500M -1.33200M
Change to liabilities - - - 0.54M 2.33M
Total cashflows from investing activities -0.03900M 6.32M -1.49900M -10.16400M -1.33200M
Net borrowings 1.12M -10.89600M 0.27M 5.61M 19.46M
Total cash from financing activities 11.52M -1.52900M 42.16M 17.25M 27.11M
Change to operating activities - - - -1.68300M 0.04M
Net income -26.17300M -39.40000M -49.50400M -29.91800M -9.74000M
Change in cash -6.96600M -16.66600M 10.49M -31.95600M -8.92900M
Begin period cash flow 12.21M 28.88M 18.39M 50.35M 59.27M
End period cash flow 5.25M 12.21M 28.88M 18.39M 50.35M
Total cash from operating activities -18.54600M -21.32600M -30.17100M -39.01100M -34.62400M
Issuance of capital stock 10.40M 9.24M 53.42M 11.46M 9.25M
Depreciation 1.50M 1.65M 1.71M 1.02M 0.95M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 0.03M -0.03100M 0.00600M -0.00200M 0.15M
Change to account receivables 0.06M 0.08M 0.05M -0.14000M -0.02800M
Sale purchase of stock - - - 11.77M 7.80M
Other cashflows from financing activities 1.50M 0.12M -0.20000M 5.92M 18.02M
Change to netincome - - - 8.35M 10.66M
Capital expenditures 0.04M 0.01M 0.33M 5.18M 1.33M
Change receivables - - - -0.14000M -0.02800M
Cash flows other operating - - - -19.71700M -38.95800M
Exchange rate changes - - - - -0.08500M
Cash and cash equivalents changes - - - -31.92600M -8.92900M
Change in working capital -3.35300M 3.21M -0.19100M -1.54000M 1.00M
Stock based compensation 6.38M 7.95M 9.12M 8.51M 12.38M
Other non cash items 3.10M 5.26M 8.70M -17.08500M -37.59500M
Free cash flow -18.58500M -21.34100M -30.50100M -44.19000M -35.95600M

Peer Comparison

Sector: Consumer Defensive Industry: Packaged Foods

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CLNN
Clene Inc.		 -0.06 1.02% 5.83 - - 372.19 7.83 447.55 -1.1292
NSRGF
Nestle SA		 - -% 98.25 26.86 18.76 3.13 7.10 3.81 21.70
NSRGY
Nestle SA ADR		 1.83 1.88% 99.15 26.82 18.66 3.18 7.07 3.81 21.70
GPDNF
Danone S.A		 1.67 2.22% 77.05 25.33 17.39 1.97 2.55 1.88 11.70
DANOY
Danone PK		 0.20 1.31% 15.49 24.23 17.64 1.88 2.57 1.88 11.70

Reports Covered

Stock Research & News

View All

Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Clene Inc.

6550 South Millrock Drive, Salt Lake City, UT, United States, 84121

Key Executives

Name Title Year Born
Mr. Robert Etherington MBA CEO, Pres & Director 1967
Mr. Mark G. Mortenson Co-Founder & Chief Science Officer 1958
Dr. Robert Glanzman M.D. Chief Medical Officer 1957
Mr. Morgan R. Brown CPA, CPA, M.B.A., MBA Chief Financial Officer 1968
Mr. Jerry Miraglia J.D. Gen. Counsel & Corp. Sec. NA
Mr. Michael T. Hotchkin Chief Devel. Officer NA
Ms. Mary Anne Mcneil Head of HR NA
Dr. Tae Heum Jeong D. Mgt. Consultant 1971
Mr. Robert Etherington MBA CEO, President & Director 1967
Mr. Morgan R. Brown CPA, M.B.A. Chief Financial Officer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.